<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-90278</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension</dc:title>
<dc:description xml:lang="en">Purpose: This study was undertaken to compare the ocular haemodynamic effects ofCombigan® versus placebo in patients with ocular hypertension (OHT).Methods: Thirty patients with OHT were included in a controlled, randomised, double blindstudy in two parallel groups; 15 were randomised to receive Combigan® and 15 to receiveplacebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurementsof the ophthalmic artery (OA) and central retinal artery (CRA) were taken usingcolour Doppler imaging(CDI) ultrasound, concurrently with intraocular pressure (IOP).                     Results: Combigan® significantly reduced IOP after 3 months of treatment (P = 0.001), whereasplacebo showed no significant change in IOP. The baseline haemodynamic parameters weresimilar between treatment and placebo groups. Patients treated with Combigan® showed astatistically significant decrease in CRA resistive index (P = 0.007).Conclusions: Patients treated for 3 months with Combigan® showed a significant decrease ofCRA resistive index that could be explained by the decrease in IOP(AU)</dc:description>
<dc:creator>Rebolleda, G</dc:creator>
<dc:creator>García-Pérez, J. L</dc:creator>
<dc:creator>Muñoz-Negrete, F. J</dc:creator>
<dc:creator>Puerto-Hernández, B</dc:creator>
<dc:creator>González-Gordaliza, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Propósito: Estudiar los cambios hemodinámicos retrobulbares mediante ecografía dopplercolor, en pacientes hipertensos oculares (HTO) en tratamiento con Combigan® versus placebo.Método: Treinta pacientes randomizados en 2 grupos paralelos fueron incluidos en un estudioprospectivo y a doble ciego; quince de ellos en tratamiento con Combigan® y quince entratamiento con placebo, durante un periodo de 3 meses. Se obtuvieron medidas de la presiónintraocular (PIO) y del flujo sanguíneo a nivel de la arteria central de la retina (ACR) y la arteriaoftámica en el momento basal y a los 3 meses.Resultados: Combigan® redujo significativamente la PIO tras tres meses de tratamiento(p = 0,001). Los parámetros hemodinámicos basales fueron similares entre los grupos placeboy tratamiento. Los pacientes tratados con Combigan® mostraron un descenso estadísticamentesignificativo del índice de resistencia de la ACR (p = 0,007).Conclusiones: Los pacientes tratados durante 3. meses con Combigan® mostraron un descensoestadísticamente significativo del índice de resistenciade la ACR que podría explicarsepor el descenso de PIO(AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;86(2): 42-46, feb. 2011. tab</dc:source>
<dc:identifier>ibc-90278</dc:identifier>
<dc:title xml:lang="es">Efecto de Combigan® versus placebo en el flujo sanguíneo ocular en pacientes hipertensos oculares</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28204^s22032</dc:subject>
<dc:subject>^d12579^s29166</dc:subject>
<dc:subject>^d31994^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14455^s22074</dc:subject>
<dc:subject>^d5225^s22040</dc:subject>
<dc:subject>^d10061^s29166</dc:subject>
<dc:subject>^d28204^s29166</dc:subject>
<dc:type>article</dc:type>
<dc:date>201102</dc:date>
</metadata>
</record>
</ibecs-document>
